Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies.

Lynce F, Wang H, Petricoin EF, Pohlmann PR, Smaglo B, Hwang J, He AR, Subramaniam DS, Deeken J, Marshall J, Pishvaian MJ.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1145-1151. doi: 10.1007/s00280-019-03947-7. Epub 2019 Sep 19.

PMID:
31538230
2.

Workup and Management of Immune-Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment.

Hsu C, Marshall JL, He AR.

Oncologist. 2019 Sep 9. pii: theoncologist.2018-0162. doi: 10.1634/theoncologist.2018-0162. [Epub ahead of print]

PMID:
31501270
3.

Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors.

Singh BP, Marshall JL, He AR.

Oncologist. 2019 Sep 6. pii: theoncologist.2018-0304. doi: 10.1634/theoncologist.2018-0304. [Epub ahead of print]

PMID:
31492768
4.

Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma.

Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM.

Cancer Res. 2019 Sep 1;79(17):4326-4330. doi: 10.1158/0008-5472.CAN-19-0803.

PMID:
31481419
5.

A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Tesfaye AA, Wang H, Hartley ML, He AR, Weiner L, Gabelia N, Kapanadze L, Shezad M, Brody JR, Marshall JL, Pishvaian MJ.

J Pancreat Cancer. 2019 May 2;5(1):12-21. doi: 10.1089/pancan.2019.0003. eCollection 2019.

6.

Reducing NETO2 expression prevents human nasopharyngeal carcinoma (NPC) progression by suppressing metastasis and inducing apoptosis.

He AR, Zhu Q, Gao S.

Biochem Biophys Res Commun. 2019 May 28;513(2):494-501. doi: 10.1016/j.bbrc.2019.03.061. Epub 2019 Apr 8.

PMID:
30975469
7.

First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.

He AR, Cohen RB, Denlinger CS, Sama A, Birnbaum A, Hwang J, Sato T, Lewis N, Mynderse M, Niland M, Giles J, Wallin J, Moser B, Zhang W, Walgren R, Plimack ER.

Oncologist. 2019 Sep;24(9):e930-e942. doi: 10.1634/theoncologist.2018-0411. Epub 2019 Mar 4.

PMID:
30833489
8.

The Role of Angiogenesis in Hepatocellular Carcinoma.

Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS.

Clin Cancer Res. 2019 Feb 1;25(3):912-920. doi: 10.1158/1078-0432.CCR-18-1254. Epub 2018 Oct 1. Review.

PMID:
30274981
9.

Detection of a lipid peroxidation-induced DNA adduct across liver disease stages.

Coia H, Ma N, He AR, Kallakury B, Berry DL, Permaul E, Makambi KH, Fu Y, Chung FL.

Hepatobiliary Surg Nutr. 2018 Apr;7(2):85-97. doi: 10.21037/hbsn.2017.06.01.

10.

A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.

Pishvaian MJ, Slack RS, Jiang W, He AR, Hwang JJ, Hankin A, Dorsch-Vogel K, Kukadiya D, Weiner LM, Marshall JL, Brody JR.

Cancer. 2018 Jun 1;124(11):2337-2346. doi: 10.1002/cncr.31309. Epub 2018 Mar 26.

11.

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, Cesari R, Chen Y, Davis CB, Huang B, Thall AD, Gopal AK.

Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. doi: 10.1158/1078-0432.CCR-17-1922. Epub 2018 Mar 16.

12.

A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Hartley M, Cheema AK, Smaglo B, Hwang JJ, He AR, Weiner LM, Marshall JL, Giaccone G, Liu S, Luecht J, Spiegel JY, Pishvaian MJ.

Cancer Chemother Pharmacol. 2018 Mar;81(3):587-596. doi: 10.1007/s00280-018-3533-8. Epub 2018 Feb 1.

PMID:
29392450
13.

Regorafenib in advanced hepatocellular carcinoma (HCC): considerations for treatment.

Kim K, Jha R, Prins PA, Wang H, Chacha M, Hartley ML, He AR.

Cancer Chemother Pharmacol. 2017 Nov;80(5):945-954. doi: 10.1007/s00280-017-3431-5. Epub 2017 Sep 20.

PMID:
28932966
14.

An endogenous DNA adduct as a prognostic biomarker for hepatocarcinogenesis and its prevention by Theaphenon E in mice.

Fu Y, Silverstein S, McCutcheon JN, Dyba M, Nath RG, Aggarwal M, Coia H, Bai A, Pan J, Jiang J, Kallakury B, Wang H, Zhang YW, Giaccone G, He AR, Chung FL.

Hepatology. 2018 Jan;67(1):159-170. doi: 10.1002/hep.29380. Epub 2017 Nov 13.

15.

Systemic therapy for advanced hepatocellular carcinoma: an update.

Desai JR, Ochoa S, Prins PA, He AR.

J Gastrointest Oncol. 2017 Apr;8(2):243-255. doi: 10.21037/jgo.2017.02.01. Review.

16.

A STORM in a teacup?-the challenges of adjuvant therapy in hepatocellular carcinoma (HCC).

Shetty K, He AR.

Transl Gastroenterol Hepatol. 2016 Mar 16;1:2. doi: 10.21037/tgh.2016.03.10. eCollection 2016. No abstract available.

17.

Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic cancer.

Tian X, Shivapurkar N, Wu Z, Hwang JJ, Pishvaian MJ, Weiner LM, Ley L, Zhou D, Zhi X, Wellstein A, Marshall JL, He AR.

Oncol Lett. 2016 Mar;11(3):1645-1650. Epub 2016 Jan 13.

18.

Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC.

Gabrielson A, Wu Y, Wang H, Jiang J, Kallakury B, Gatalica Z, Reddy S, Kleiner D, Fishbein T, Johnson L, Island E, Satoskar R, Banovac F, Jha R, Kachhela J, Feng P, Zhang T, Tesfaye A, Prins P, Loffredo C, Marshall J, Weiner L, Atkins M, He AR.

Cancer Immunol Res. 2016 May;4(5):419-30. doi: 10.1158/2326-6066.CIR-15-0110. Epub 2016 Mar 11.

19.

Outcomes and Predictors of Toxicity after Selective Internal Radiation Therapy Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma.

Gabrielson A, Miller A, Banovac F, Kim A, He AR, Unger K.

Front Oncol. 2015 Dec 23;5:292. doi: 10.3389/fonc.2015.00292. eCollection 2015.

20.

Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.

Wu Z, Gabrielson A, Hwang JJ, Pishvaian MJ, Weiner LM, Zhuang T, Ley L, Marshall JL, He AR.

Cancer Chemother Pharmacol. 2015 Dec;76(6):1309-14. doi: 10.1007/s00280-015-2855-z. Epub 2015 Oct 27.

PMID:
26507197
21.

Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.

Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Smaglo B, Jha R, Dorsch-Vogel K, Wang H, He AR.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1073-9. doi: 10.1007/s00280-015-2852-2. Epub 2015 Oct 8.

22.

Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.

Cheng AL, Kang YK, He AR, Lim HY, Ryoo BY, Hung CH, Sheen IS, Izumi N, Austin T, Wang Q, Greenberg J, Shiratori S, Beckman RA, Kudo M; Investigators’ Study Group.

J Hepatol. 2015 Oct;63(4):896-904. doi: 10.1016/j.jhep.2015.06.001. Epub 2015 Jun 10.

PMID:
26071796
23.

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.

Deeken JF, Wang H, Subramaniam D, He AR, Hwang J, Marshall JL, Urso CE, Wang Y, Ramos C, Steadman K, Pishvaian MJ.

Cancer. 2015 May 15;121(10):1645-53. doi: 10.1002/cncr.29224. Epub 2015 Jan 29.

24.

Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.

Subramaniam D, He AR, Hwang J, Deeken J, Pishvaian M, Hartley ML, Marshall JL.

Curr Cancer Drug Targets. 2015;14(9):775-93. Review.

PMID:
25435079
25.

βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin.

Zhi X, Lin L, Yang S, Bhuvaneshwar K, Wang H, Gusev Y, Lee MH, Kallakury B, Shivapurkar N, Cahn K, Tian X, Marshall JL, Byers SW, He AR.

Hepatology. 2015 Feb;61(2):598-612. doi: 10.1002/hep.27558.

26.

Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study.

Weinberg BA, Wang H, Yang X, Wu CS, Pishvaian MJ, He AR, Marshall JL, Hwang JJ.

Gastrointest Cancer Res. 2014 May;7(3-4):91-7.

27.

Stereotactic Body Radiation Therapy (SBRT) Combined With Chemotherapy for Unresected Pancreatic Adenocarcinoma.

Gurka MK, Kim C, He AR, Charabaty A, Haddad N, Turocy J, Johnson L, Jackson P, Weiner LM, Marshall JL, Collins SP, Pishvaian MJ, Unger K.

Am J Clin Oncol. 2017 Apr;40(2):152-157. doi: 10.1097/COC.0000000000000118.

28.

Transcriptional regulation of STAT3 by SPTBN1 and SMAD3 in HCC through cAMP-response element-binding proteins ATF3 and CREB2.

Lin L, Yao Z, Bhuvaneshwar K, Gusev Y, Kallakury B, Yang S, Shetty K, He AR.

Carcinogenesis. 2014 Nov;35(11):2393-403. doi: 10.1093/carcin/bgu163. Epub 2014 Aug 5.

PMID:
25096061
29.

Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial.

Rimassa L, Porta C, Borbath I, Daniele B, Finn RS, Raoul JL, Schwartz LH, He AR, Trojan J, Peck-Radosavljevic M, Abbadessa G, Goldberg T, Santoro A, Bruix J.

Hepat Oncol. 2014 Apr;1(2):181-188. doi: 10.2217/hep.14.3. Epub 2014 Jan 29. Review.

30.

Yttrium-90 Radioembolization in Patients with Hepatocellular Carcinoma Who have Previously Received Sorafenib.

Rana N, Ju AW, Bazylewicz M, Kallakury B, He AR, Unger KR, Lee JS.

Front Oncol. 2013 Dec 30;3:323. doi: 10.3389/fonc.2013.00323. eCollection 2013.

31.

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.

Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M.

Cancer Med. 2013 Dec;2(6):925-32. doi: 10.1002/cam4.137. Epub 2013 Oct 25.

32.

Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations.

He AR, Goldenberg AS.

Therap Adv Gastroenterol. 2013 Nov;6(6):447-58. doi: 10.1177/1756283X13498540.

33.

A phase I study of liposomal-encapsulated docetaxel (LE-DT) in patients with advanced solid tumor malignancies.

Deeken JF, Slack R, Weiss GJ, Ramanathan RK, Pishvaian MJ, Hwang J, Lewandowski K, Subramaniam D, He AR, Cotarla I, Rahman A, Marshall JL.

Cancer Chemother Pharmacol. 2013 Mar;71(3):627-33. doi: 10.1007/s00280-012-2048-y. Epub 2012 Dec 30.

34.

A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.

Pishvaian MJ, Slack R, Koh EY, Beumer JH, Hartley ML, Cotarla I, Deeken J, He AR, Hwang J, Malik S, Firozvi K, Liu M, Elston B, Strychor S, Egorin MJ, Marshall JL.

Cancer Chemother Pharmacol. 2012 Dec;70(6):843-53. doi: 10.1007/s00280-012-1969-9. Epub 2012 Sep 27.

35.

Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.

Shivapurkar N, Mikhail S, Navarro R, Bai W, Marshall J, Hwang J, Pishvaian M, Wellstein A, He AR.

Int J Colorectal Dis. 2013 Jun;28(6):887. doi: 10.1007/s00384-012-1560-1. Epub 2012 Aug 15. No abstract available.

36.

Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma.

Majumdar A, Curley SA, Wu X, Brown P, Hwang JP, Shetty K, Yao ZX, He AR, Li S, Katz L, Farci P, Mishra L.

Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):530-8. doi: 10.1038/nrgastro.2012.114. Epub 2012 Jun 19. Review.

37.

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Pishvaian MJ, Marshall JL, Wagner AJ, Hwang JJ, Malik S, Cotarla I, Deeken JF, He AR, Daniel H, Halim AB, Zahir H, Copigneaux C, Liu K, Beckman RA, Demetri GD.

Cancer. 2012 Nov 1;118(21):5403-13. doi: 10.1002/cncr.27526. Epub 2012 May 8.

38.

Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors.

Kunz PL, He AR, Colevas AD, Pishvaian MJ, Hwang JJ, Clemens PL, Messina M, Kaleta R, Abrahao F, Sikic BI, Marshall JL.

Invest New Drugs. 2012 Dec;30(6):2364-70. doi: 10.1007/s10637-012-9800-3. Epub 2012 Feb 14.

39.

Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.

Zhang JX, Li DQ, He AR, Motwani M, Vasiliou V, Eswaran J, Mishra L, Kumar R.

Hepatology. 2012 Jun;55(6):1840-51. doi: 10.1002/hep.25566.

40.

Liver cancer stem cells.

Mikhail S, He AR.

Int J Hepatol. 2011;2011:486954. doi: 10.4061/2011/486954. Epub 2011 Jun 30.

41.

Current problems with systemic treatment of advanced hepatocellular cancer.

He AR, Soe K, El Zouhairi M.

Curr Probl Cancer. 2010 Mar-Apr;34(2):131-49. doi: 10.1016/j.currproblcancer.2010.03.001. Review. No abstract available.

PMID:
20417353
42.

Evaluation of hypertension as a marker of bevacizumab efficacy.

Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR.

J Gastrointest Cancer. 2009;40(3-4):101-8. doi: 10.1007/s12029-009-9104-9.

43.

The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, Mishra L, He AR.

Oncogene. 2009 Feb 19;28(7):961-72. doi: 10.1038/onc.2008.448. Epub 2009 Jan 12.

44.

Liver stem cells and hepatocellular carcinoma.

Mishra L, Banker T, Murray J, Byers S, Thenappan A, He AR, Shetty K, Johnson L, Reddy EP.

Hepatology. 2009 Jan;49(1):318-29. doi: 10.1002/hep.22704. Review.

45.

Biologic therapies for advanced pancreatic cancer.

He AR, Lindenberg AP, Marshall JL.

Expert Rev Anticancer Ther. 2008 Aug;8(8):1331-8. doi: 10.1586/14737140.8.8.1331. Review.

PMID:
18699769
46.

Stem cells in gastrointestinal cancers.

He AR, Mendelson J, Blake T, Mishra L, Marshall JL.

Dis Markers. 2008;24(4-5):217-22. Review. No abstract available.

47.

Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling.

Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, Ressom HW, Rashid A, He AR, Mendelson JS, Jessup JM, Shetty K, Zasloff M, Mishra B, Reddy EP, Johnson L, Mishra L.

Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2445-50. doi: 10.1073/pnas.0705395105. Epub 2008 Feb 8.

48.

Acute venous disease: venous thrombosis and venous trauma.

Meissner MH, Wakefield TW, Ascher E, Caprini JA, Comerota AJ, Eklof B, Gillespie DL, Greenfield LJ, He AR, Henke PK, Hingorani A, Hull RD, Kessler CM, McBane RD, McLafferty R.

J Vasc Surg. 2007 Dec;46 Suppl S:25S-53S. doi: 10.1016/j.jvs.2007.08.037. Review.

49.

Clinical experiences with G17DT in gastrointestinal malignancies.

He AR, Marshall JL.

Expert Rev Anticancer Ther. 2006 Apr;6(4):487-92. Review.

PMID:
16613537
50.

Biologic therapy for colon cancer.

He AR, Marshall J.

Clin Adv Hematol Oncol. 2005 Jul;3(7):555-61. Review.

PMID:
16167038

Supplemental Content

Support Center